Navigation Links
Encision Reports Profitable First Fiscal Quarter Results
Date:7/30/2009

BOULDER, Colo., July 30 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its first quarter of fiscal year 2010.

Net sales for the three-months ended June 30, 2009 totaled $3.2 million, representing a 3% increase over net sales of $3.1 million for the prior fiscal year's first quarter. The Company recorded net income of $163 thousand or $.03 per share for the first quarter of fiscal year 2010, compared to a net loss of $164 thousand or ($.03) per share for the first quarter of fiscal year 2009. Gross profit margin for the first quarter of fiscal year 2010 was 64%, as compared to 60.3% for the first quarter of fiscal year 2009, a 3.7% increase resulting from production efficiencies and an increase to inventory which resulted in a higher absorption of overhead costs to inventory and a decrease to cost of sales.

"We are pleased with the start to our first quarter of fiscal year 2010, especially with the turnaround from last year's first quarter net loss. Net income increased from last year's first quarter net loss as a result of a slight increase in sales income, increased gross profit margin and reduced operating expenses," said Jack Serino, President and CEO of Encision Inc.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM(R) Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in our filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

                                  Encision Inc.
                            Condensed Balance Sheets
                             (Amounts in thousands)

                                            June 30,     March 31,
                                             2009         2009
                                          (Unaudited)   (Audited)
                                          -----------   ---------
    ASSETS
    Cash and cash equivalents                $126          $85
    Accounts receivable, net                1,235        1,264
    Inventories, net                        2,459        2,505
    Prepaid expenses                          110           36
                                              ---           --
      Total current assets                  3,930        3,890
                                            -----        -----
    Equipment, net                            884          840
    Patents, net                              223          216
    Other assets                               18           24
                                               --           --
      Total assets                         $5,055       $4,970
                                           ------       ------
    LIABILITIES AND SHAREHOLDERS'
     EQUITY
    Accounts payable                         $662         $745
    Accrued compensation                      311          406
    Other accrued liabilities                 360          367
    Line of credit                            275          191
                                              ---          ---
      Total current liabilities             1,608        1,709
                                            -----        -----
    Common stock and additional
     paid-in capital                       19,582       19,560
    Accumulated (deficit)                 (16,135)     (16,299)
                                          -------      -------
      Total shareholders' equity            3,447        3,261
                                            -----        -----
      Total liabilities and
       shareholders' equity                $5,055       $4,970
                                           ------       ------


                                  Encision Inc.
                     Condensed Statements of Operations
             (Amounts in thousands, except per share information)

                                                 (Unaudited)
                                              Three Months Ended
                                              ------------------
                                            June 30,       June 30,
                                              2009           2008
                                            --------       --------
    Net sales                               $3,174         $3,094
    Cost of sales                            1,142          1,229
                                             -----          -----
    Gross profit                             2,032          1,865
                                             -----          -----
    Operating expenses:
      Sales and marketing                    1,199          1,374
      General and administrative               354            367
      Research and development                 301            289
                                               ---            ---
       Total operating expenses              1,854          2,030
                                             -----          -----
    Operating income (loss)                    178           (165)
    Interest and other income
     (expense), net                            (15)             1
                                               ---            ---
    Income (loss) before provision
     for income taxes                          163           (164)
    Provision for income taxes                   -              -
                                               ---            ---
    Net income (loss)                         $163          $(164)
                                              ====          =====
    Net income (loss) per
     share-basic and diluted                 $0.03         $(0.03)
    Basic and diluted weighted
     average number of shares                6,455          6,450


'/>"/>
SOURCE Encision Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Encision Reports Fourth Quarter and Fiscal Year 2009 Results
2. Encision Announces Quoting of Common Stock on the OTC Bulletin Board
3. Encision Pursues Transfer of Quotation to OTC Bulletin Board
4. Encision Reports First Fiscal Quarter Results
5. Encision Reports Fourth Quarter and Fiscal Year 2008 Results
6. Encision Moves Power and Safety to Surgeons Fingertips
7. Encision Supports National Patient Safety Awareness Week
8. Encision Reports Third Fiscal Quarter Results
9. American Stock Exchange Accepts Encisions Plan to Regain Compliance
10. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
11. Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology: